Myalgia in patients can be associated with a large array of conditions, including injuries, infections and inflammations. Treatment for myalgia may include the use of oral, topical and injectable medicines (IM). However, the use of IM has been restricted by the World Health Organization due to the common hazards associated with inappropriate medicine use, risks of disease transmission and more expensive spending for using IM. Accordingly, the Ministry of Health of Indonesia (MoH) has limited the use at the level of ≤1% in every primary care center (Puskesmas) across the nation. The aim of this study was to report and evaluate rational drug use injection in myalgia in a Puskesmas in Pamekasan, Indonesia.
This study reviewed official documents, such as rational drug use report, medicine use databases and drug request report. The documents were obtained from the district health office or public domain from 2014 to 2018. Data were then collated, extracted and presented as frequencies.
The average rate of use of IM for myalgia in Pamekasan was 36.15%. All 20 Puskesmas in Pamekasan conducted injection practice above the recommended level, thus reflecting a major gap between practice and policy implementation. This study implies that a substantial effort is needed to enforce the policy.
The use of IM for myalgia treatment in Pamekasan from 2014 to 2018 was significantly higher than the recommended level, thus reflecting a major problem in the practice. This is an alarming call for the local healthcare stakeholders to improve such a situation.
The authors would like to thank the Pamekasan District Health Office and East Java Province Health Office for providing the data related to the use of injection drugs for myalgia.
Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: The authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ institutional review board or equivalent committee. (070/8324/209.4/2019). This study has obtained permission from the Government of East Java Province and District Health Office Pamekasan, Indonesia.
 Tomaszewski M, Stepien KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep 2011;63:859–66.10.1016/S1734-1140(11)70601-6Search in Google Scholar
 Destiani DP, Naja S, Nurhadiyah A, Halimah E, Febrina E. Outpatient prescribing patterns: observational studies using WHO prescribing criteria in one of the Bandung health facilities. Indones Clin Pharm J 2016;5:225–31.10.15416/ijcp.2016.5.3.225Search in Google Scholar
 Kardela W, Andrajati R, Supardi S. Comparison of rational drug use based on WHO indicators in district health centers between Depok City and South Jakarta. Indones Pharm J 2014;4:91–102.Search in Google Scholar
 Sisay M, Mengistu G, Molla B, Amare F, Gabriel T. Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. BMC Health Serv Res 2017;17:161.10.1186/s12913-017-2097-3Search in Google Scholar PubMed PubMed Central
 Ministry of Health of the Republic of Indonesia. Module for the use of rational drugs. Jakarta: Ministry of Health of the Republic of Indonesia, 2015.Search in Google Scholar
 Ministry of Health of the Republic of Indonesia. Mobilization module using rational medication. Jakarta: Ministry of Health of the Republic of Indonesia, 2012.Search in Google Scholar
 World Health Organization. Promoting rational use of medicine: core component. WHO Policy Perspective on Medicine. Geneva: World Health Organization, 2002.Search in Google Scholar
 Sadikin ZD. Rational drug use. J Indon Med Assoc 2011;61:4.Search in Google Scholar
© 2019 Walter de Gruyter GmbH, Berlin/Boston